

June 7, 2025

The Manager – Listing  
**BSE Limited**  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sir(s),

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Disclosure of ESG Rating**

We wish to inform you that SES ESG Research Private Limited (SES) has, vide its Environmental, Social, and Governance (ESG) Report as received by AstraZeneca Pharma India Limited ('the Company'), assigned an ESG Score (Adjusted) as 64.9 (Grade B) based on publicly available information pertaining to FY 2023-24.

Please note that the Company has not engaged SES for ESG Rating. SES has independently prepared the report based on publicly available information for FY 2023-24.

This intimation is in compliance with Regulation 30 of SEBI Listing Regulations read with the SEBI Circular SEBI/HO/CFD/CFD-PoD- 1/P/CIR/2023/123 dated July 13, 2023.

Further, the aforementioned report was accessed on June 5, 2025 and some time was spent in good faith for evaluation of the contents laid in the report.

Kindly take the above information on record.

Thanking you,

For AstraZeneca Pharma India Limited

**Manasa. R**  
Company Secretary